Úlceras digitais numa doente com esclerose sistémica

LeRoy EC, Medsger TA. Criteria for the classification of early Systemic Sclerosis. J Rheumatol 2001; 28:1573-1576.

Bakst R, Merola JF, Franks AG et al. Raynaud phenomenon: Pathogenesis and management. J Am Acad Dermatol. 2008 59(4):633-653.

Yamamoto T, Katayama I, Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 1998; 25:314-317.

Yamame K, Miyautchi T, Suzuki N et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992; 19:1566-1571.

Korn JH, Mayes M, Cerinic MM et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004; 50:3985-3993.

Cerinic MM, Denton CP, Furst D et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-bind, placebo-controlled trial. AnnRheum Dis 2011 70(1):32-38.